Research library
Thymosin peptides, explained
12 guides, organized by the question you are trying to answer.
Research Guides
Thymosin alpha-1, beta-4 and TB-500: identify the molecule first
A practical identity map that keeps immune, tissue-repair and fragment research from being pooled together.
Thymosin alpha-1 in cancer research: adjunct signals are not cure claims
Read the metastatic-melanoma combination trial by comparator, endpoint and statistical result.
Athletes: beta-4 and TB-500 are named in the 2026 prohibited list
Separate sport eligibility from approval, prescribing and claims about injury recovery.
Thymosin beta-4 trials: keep eye drops, wound treatment and fragments separate
A route-specific look at two early beta-4 studies, including negative primary endpoints in the dry-eye trial.
Thymosin alpha-1 COVID studies: why conflicting results need design context
Compare a small hospitalized randomized trial with a multicenter cohort without turning either into an outpatient or long-COVID claim.
Thymosin alpha-1 in hepatitis B: what did the randomized comparison test?
Why two active dose groups cannot answer the same question as a placebo or current-treatment comparison.
Hepatitis C research: Thymosin alpha-1 alone and in combination are different interventions
Read a negative pilot study alongside an interferon-combination trial without borrowing benefits across regimens.
Intravenous beta-4 phase I studies: exposure data are not repair outcomes
Understand what healthy-volunteer safety and pharmacokinetic studies can establish, and why they do not validate TB-500.
Thymosin status: approval, compounding review and product identity are separate checks
Read dated FDA records without mistaking a withdrawn nomination, committee discussion or foreign product name for an authorization.
Reset-alpha and TESTS: biomarkers and survival answer different questions
Compare a short sepsis trial report with the larger TESTS publication without treating every positive measure as equivalent evidence.
TESTS: the large Thymosin alpha-1 sepsis trial was negative overall
Read the randomized trial with its May 2025 correction, including corrected mortality hazard ratios and limits.
Thymosin alpha-1 and vaccine antibody research: what was measured?
Why an antibody-response study does not automatically establish fewer infections or a recommendation for vaccine adjunct use.
